Wedbush analyst David Nierengarten downgraded Fate Therapeutics to Neutral from Outperform with a $7 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FATE:
- Here’s Why Fate Therapeutics (NASDAQ:FATE) Stock Is Sliding Down
- Fate Therapeutics downgraded on lack of catalysts at Cowen
- Fate Therapeutics downgraded to Market Perform from Outperform at Cowen
- Fate Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Fate Therapeutics downgraded to Market Perform from Outperform at BMO Capital